argenx NV ADR - Asset Resilience Ratio
argenx NV ADR (ARGX) has an Asset Resilience Ratio of 10.93% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of argenx NV ADR for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2025)
This chart shows how argenx NV ADR's Asset Resilience Ratio has changed over time. For market capitalisation and broader financial context, see argenx NV ADR market capitalisation.
Liquid Assets Composition Over Time
This chart breaks down argenx NV ADR's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $948.75 Million | 10.93% |
| Total Liquid Assets | $948.75 Million | 10.93% |
Asset Resilience Insights
- Moderate Liquidity: argenx NV ADR has 10.93% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
argenx NV ADR Industry Peers by Asset Resilience Ratio
Compare argenx NV ADR's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653 |
Biotechnology | 2.21% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Abivax SA American Depositary Shares
NASDAQ:ABVX |
Biotechnology | 2.34% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
Annual Asset Resilience Ratio for argenx NV ADR (2012–2025)
The table below shows the annual Asset Resilience Ratio data for argenx NV ADR.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 10.93% | $948.75 Million | $8.68 Billion | -19.37pp |
| 2024-12-31 | 30.29% | $1.88 Billion | $6.20 Billion | +5.39pp |
| 2023-12-31 | 24.90% | $1.13 Billion | $4.54 Billion | -19.51pp |
| 2022-12-31 | 44.41% | $1.39 Billion | $3.13 Billion | +9.25pp |
| 2021-12-31 | 35.16% | $1.00 Billion | $2.85 Billion | +0.95pp |
| 2020-12-31 | 34.20% | $779.65 Million | $2.28 Billion | -35.88pp |
| 2019-12-31 | 70.08% | $1.13 Billion | $1.61 Billion | +21.07pp |
| 2018-12-31 | 49.01% | $324.33 Million | $661.70 Million | +3.48pp |
| 2017-12-31 | 45.54% | $202.64 Million | $444.98 Million | +39.08pp |
| 2016-12-31 | 6.46% | $7.18 Million | $111.24 Million | -8.37pp |
| 2015-12-31 | 14.82% | $7.45 Million | $50.25 Million | -34.63pp |
| 2014-12-31 | 49.45% | $28.93 Million | $58.51 Million | +47.45pp |
| 2013-12-31 | 2.00% | $690.44K | $34.54 Million | -4.06pp |
| 2012-12-31 | 6.06% | $1.39 Million | $22.93 Million | -- |
About argenx NV ADR
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgarti… Read more